NCT03562611

Brief Summary

The purpose of this study is to evaluate the postoperative pain and discomfort using flurbiprofen axetil or nalbuphine administration after orbital decompression under general anesthesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P25-P50 for not_applicable surgery

Timeline
Completed

Started Jun 2018

Shorter than P25 for not_applicable surgery

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2018

Completed
1 day until next milestone

Study Start

First participant enrolled

June 8, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 19, 2018

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 8, 2018

Completed
22 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2018

Completed
Last Updated

December 26, 2018

Status Verified

December 1, 2018

Enrollment Period

3 months

First QC Date

June 7, 2018

Last Update Submit

December 22, 2018

Conditions

Keywords

postoperative paingeneral anesthesiapostoperative discomfort

Outcome Measures

Primary Outcomes (1)

  • Pain after orbital decompression

    Pain levels measured using Numerical Rating Scale (NRS) ranging from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable ; this scale has been confirmed to be sensitive and reliable.Clinically significant postoperative pain was considered serious pain (NRS score ≥5).

    24 hour after recovery

Secondary Outcomes (1)

  • Discomfort after orbital decompression

    24 hour after recovery

Study Arms (3)

flurbiprofen axetil

ACTIVE COMPARATOR

flurbiprofen axetil intraoperative administration 100mg

Drug: Flurbiprofen Axetil

nalbuphine

EXPERIMENTAL

nalbuphine intraoperative administration 0.1mg/kg

Drug: Nalbuphine

nalbuphine and flurbiprofen axetil

EXPERIMENTAL

flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg

Drug: Nalbuphine and Flurbiprofen Axetil

Interventions

Nalbuphine administration during surgery

nalbuphine

Flurbiprofen axetil administration during surgery

flurbiprofen axetil

Nalbuphine and Flurbiprofen Axetil administration during surgery

nalbuphine and flurbiprofen axetil

Eligibility Criteria

Age16 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • years old
  • diagnosed as thyroid eye disease
  • bone removal orbital decompression under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status of I-II

You may not qualify if:

  • body mass index (BMI) \<18.5 or \>35
  • any uncontrolled clinical problems

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

Location

MeSH Terms

Conditions

PainPain, Postoperative

Interventions

Nalbuphineflurbiprofen axetil

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic Processes

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Huijing Ye

    Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 7, 2018

First Posted

June 19, 2018

Study Start

June 8, 2018

Primary Completion

September 8, 2018

Study Completion

September 30, 2018

Last Updated

December 26, 2018

Record last verified: 2018-12

Locations